Verici Logo

Media

Result of AGM and voting results

June 28, 2022
Verici DX announces that at the Annual General Meeting
Keep Reading

Distribution of Verici Dx shares by EKF Diagnostics Holdings plc

June 20, 2022
Verici DX notes the announcement made by EKF Diagnostics Holdings PLC
Keep Reading

Investor Update

June 16, 2022
Sara Barrington, CEO, will provide a live presentation relating to positive data from the Tuteva™ clinical validation study via the Investor Meet Company platform
Keep Reading

Further data from Tuteva™ clinical validation study presented

June 14, 2022
Performance in blinded multi-centre trial establishes new industry standard in detection of acute kidney transplant rejection and paves way for US commercial launch in 2022
Keep Reading

Commercial Team Appointments

June 9, 2022
Verici Dx plc announces the senior appointments of Grant Harvey and Dr. Windy Tucci as Business Development Director and Medical Science Liaison Director
Keep Reading

Posting of Annual Report & Accounts and Notice of Annual General Meeting

May 25, 2022
Verici Dx plc confirms that the Annual Report and Accounts and the Notice of the 2022 Annual General Meeting have now been published
Keep Reading

Final Results and Post Year-End Update

May 19, 2022
Verici Dx plc announces its audited final results for the period ended 31 December 2021
Keep Reading

Positive results for Tuteva™ from the international clinical validation study

May 12, 2022
Performance in blinded multi-centre trial establishes new industry standard in detection of acute kidney transplant rejection and paves way for commercial launch in United States in 2022
Keep Reading

Clinical Validation Study Update

April 1, 2022
Strategic decision to expand study without impacting commercial pathway
Keep Reading
1 2 3 6
crossmenu